262 related articles for article (PubMed ID: 12749519)
1. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
Becker RV; Burke TA; McCoy MA; Trotter JP
Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
[TBL] [Abstract][Full Text] [Related]
2. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
[TBL] [Abstract][Full Text] [Related]
3. Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.
Osterhaus JT; Burke TA; May C; Wentworth C; Whelton A; Bristol S
Clin Ther; 2002 Jun; 24(6):969-89. PubMed ID: 12117086
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients.
Whelton A; Fort JG; Puma JA; Normandin D; Bello AE; Verburg KM;
Am J Ther; 2001; 8(2):85-95. PubMed ID: 11304662
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
6. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Whelton A; White WB; Bello AE; Puma JA; Fort JG;
Am J Cardiol; 2002 Nov; 90(9):959-63. PubMed ID: 12398962
[TBL] [Abstract][Full Text] [Related]
7. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Harley C; Wagner S
Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
[TBL] [Abstract][Full Text] [Related]
9. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
10. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
[TBL] [Abstract][Full Text] [Related]
11. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582
[No Abstract] [Full Text] [Related]
12. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Spiegel BM; Targownik L; Dulai GS; Gralnek IM
Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
[TBL] [Abstract][Full Text] [Related]
14. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Gertz BJ; Krupa D; Bolognese JA; Sperling RS; Reicin A
Curr Med Res Opin; 2002; 18(2):82-91. PubMed ID: 12017215
[TBL] [Abstract][Full Text] [Related]
15. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
[TBL] [Abstract][Full Text] [Related]
19. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Grover SA; Coupal L; Zowall H
Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508
[TBL] [Abstract][Full Text] [Related]
20. Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Weaver A; Alderman M; Sperling R
Am J Cardiol; 2003 May; 91(10):1291-2. PubMed ID: 12745131
[No Abstract] [Full Text] [Related]
[Next] [New Search]
